HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma.

Abstract
Complete response (CR) is associated with better outcome in patients with multiple myeloma (MM) treated with autologous transplant even though the progression-free survival (PFS) can be very variable among patients with good response. No simple and reliable prognostic scoring system, able to predict the duration of response, are so far available. Aim of this study was to identify any correlation between baseline clinical findings, response after transplant and the length of PFS, and thus develop a prognostic model. The new prognostic model was developed in a learning cohort of 549 patients with MM transplanted in five Italian hospitals. The prognostic value of this new score was confirmed in a validation cohort of 276 distinct patients with MM transplanted in two different Italian hospital. Univariate and multivariate analyses were performed using Cox models. The most important independent baseline predictor of transplant outcome, together with response after transplant, was International Staging System (ISS). We thus incorporated response to transplant and baseline ISS in a new scoring system, named response-adjusted international scoring system (RaISS), that was able to classify patients in three risk groups (low, intermediate, high) with different probabilities of progression after transplant (median PFS 35.9-15.4 months). The prognostic value of this new score was confirmed in the validation cohort. In conclusion, RaISS is a new simple and easily available scoring system that, accurately defining the risk of progression, can allow to identify patients who could deserve further treatment after transplant (consolidation, maintenance).
AuthorsAlessandro Corso, Monica Galli, Silvia Mangiacavalli, Fausto Rossini, Andrea Nozza, Cristiana Pascutto, Vittorio Montefusco, Luca Baldini, Anna Maria Cafro, Claudia Crippa, Mario Cazzola, Paolo Corradini
JournalAmerican journal of hematology (Am J Hematol) Vol. 87 Issue 2 Pg. 150-4 (Feb 2012) ISSN: 1096-8652 [Electronic] United States
PMID22189759 (Publication Type: Journal Article, Multicenter Study)
CopyrightCopyright © 2011 Wiley Periodicals, Inc.
Topics
  • Adult
  • Aged
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Middle Aged
  • Models, Statistical
  • Multiple Myeloma (diagnosis, mortality, pathology, therapy)
  • Prognosis
  • Proportional Hazards Models
  • Research Design
  • Risk Assessment
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: